Niowave, Ratio Therapeutics Sign Actinium-225 Pact

Niowave and Ratio Therapeutics ink an Actinium-225 supply pact, providing isotope access for Ratio's cancer therapy tech pipeline amid global supply constraints.

Lead

What Happened

Under the agreement, Lansing, Michigan-based Niowave will provide current Good Manufacturing Practice cGMP Actinium-225 to support Ratio's ongoing clinical development and future program advancement. The isotope directly fuels [Ac-225]RTX-2358, Ratio's lead therapeutic candidate, which targets fibroblast activation protein-alpha — a protein overexpressed in the tumor microenvironment across multiple solid tumor types.

The Niowave agreement follows a May 2026 expansion of Ratio's manufacturing partnership with PharmaLogic Holdings Corp., which extended clinical supply operations to PharmaLogic's Idaho Falls therapeutics facility to support both ongoing trials and commercialization readiness. The dual moves reflect a deliberate strategy to secure both upstream isotope supply and downstream production capacity simultaneously.

Actinium-225 Supply Landscape

That supply gap has since catalyzed a wave of infrastructure investment. In March 2026, TerraPower Isotopes announced a $450 million production facility in Philadelphia that, combined with its existing Everett, Washington site, is projected to expand Ac-225 output twenty-fold. Niowave, founded in 2005, produces the isotope through superconducting electron linear accelerators — an accelerator-based production route that operates independently of nuclear reactor availability and can scale without the geopolitical constraints that affect reactor-sourced supply.

Strategic Context

For Niowave, the Ratio agreement is the third major Actinium-225 supply partnership announced in 2026. In February, the company signed a global supply deal with Novartis (NVS) to support next-generation cancer therapy programs. That followed an expanded ten-year global agreement with AstraZeneca (AZN) finalized in late 2025. The accumulation of multi-party contracts positions Niowave as one of the sector's primary isotope infrastructure providers as both pharmaceutical majors and clinical-stage biotechs compete for secured access.

For Ratio Therapeutics, the pact addresses targeted alpha therapy's most persistent bottleneck directly. The company's proprietary cancer therapy tech platforms are designed to differentiate its pipeline from more crowded lutetium-177-based programs, but that differentiation depends entirely on reliable Actinium-225 supply. Securing Niowave as a cGMP source reduces clinical timeline risk and supports regulatory readiness for later-stage trial submissions.

Outlook

The targeted alpha therapy sector enters the second half of 2026 with more than 30 Ac-225-linked drug candidates in clinical development. Supply infrastructure, not scientific mechanism, remains the binding constraint for most programs. As candidates advance toward Phase 3 and potential commercialization, isotope supply agreements will become increasingly determinative of which programs proceed on schedule and which face costly delays. Niowave's accelerator-based production model and its growing portfolio of supply partnerships across Novartis, AstraZeneca, and now Ratio Therapeutics establish it as a central node in the emerging Ac-225 supply chain, while Ratio's dual-track approach to isotope sourcing and manufacturing capacity positions it among the better-prepared clinical-stage players in the space.

Deals